Back to top
more

Sarepta Therapeutics (SRPT)

(Real Time Quote from BATS)

$118.92 USD

118.92
378,858

-3.92 (-3.19%)

Updated Jun 17, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (SRPT) Outperforming Other Medical Stocks This Year?

Regeneron (REGN) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Regeneron (REGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sarepta's Gene Therapy Promising in Muscular Dystrophy Study

by Zacks Equity Research

Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.

Sarepta Therapeutics' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Sarepta Therapeutics.

Why Is Sarepta Therapeutics (SRPT) Up 17.3% Since Last Earnings Report?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sanghamitra Saha headshot

Do You Always Look for Earnings Beat? 5 Sectors to Play

by Sanghamitra Saha

These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.

Is Sarepta Therapeutics (SRPT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (SRPT) Outperforming Other Medical Stocks This Year?

Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data

by Zacks Equity Research

Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.

Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

by Zacks Equity Research

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q1 revenues increase year over year.

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 89.96% and 0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy

Tirthankar Chakraborty headshot

5 Stocks to Win Big This Brutal Q1 Earnings Season

by Tirthankar Chakraborty

There are certain sectors whose earnings are expected to perk up in the first quarter despite this pandemic. Such sectors include Construction, Medical, Consumer Staples and Utilities.

Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates

by Zacks Equity Research

Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.

Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -72.68% and 0.02%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs

by Zacks Equity Research

Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Are Options Traders Betting on a Big Move in Sarepta (SRPT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.

Applied Genetic Stock Up on Favorable Eye Therapy Study Data

by Zacks Equity Research

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

Sweta Killa headshot

Biotech Leading in Q4: Best ETFs & Stocks

by Sweta Killa

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Sarepta (SRPT) Looks Good: Stock Adds 7.5% in Session

by Zacks Equity Research

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Company News For Dec 24, 2019

by Zacks Equity Research

Companies in the news are: ACB, APA, ITCI, SRPT

Sarepta Signs Gene Therapy Agreement With Roche for $1.15B

by Zacks Equity Research

Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone payments.

Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up

by Zacks Equity Research

Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.